Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SAT-3247
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Satellos Completes Phase 1 Enrollment for SAT-3247 in Healthy Volunteers
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : SAT-3247
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Bloom Burton Securities Inc
Deal Size : $40.0 million
Deal Type : Public Offering
Satellos Announces Pricing of US$40M Overnight Marketed Public Offering
Details : The Company intends to use the net proceeds from the Offering to advance clinical development of SAT-3247. It is being evaluated for the treatment of Duchenne Muscular Dystrophy.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 17, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Bloom Burton Securities Inc
Deal Size : $40.0 million
Deal Type : Public Offering
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Announces First Participant Dosed in Phase 1b Trial of SAT-3247 in DMD
Details : SAT-3247 is designed as a once-daily, oral small-molecule drug that targets the root cause of muscle loss in degenerative diseases. It is being evaluated for the treatment of DMD.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Demonstrates Improved Strength in DMD Canines with SAT-3247
Details : SAT-3247 is designed as a once-daily, oral small-molecule drug that targets the root cause of muscle loss in degenerative diseases. It is being evaluated for the treatment of DMD.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Announces Filing to Start Phase 1 Trial with SAT-3247
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Receives FDA Rare Pediatric Designation for SAT-3247 in Duchenne Dystrophy
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
August 08, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Submits Filing for Phase 1 Trial with SAT-3247
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Presents Data Showing Muscle Repair from SAT-3247 in Canine Model of DMD
Details : SAT-3247 is a once-daily, oral small molecule, AAK1 inhibitor that targets the root cause of muscle loss in degenerative diseases. It is currently in investigation for duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Satellos Forms Clinical Advisory Board for SAT-3247 in Duchenne Muscular Dystrophy
Details : SAT-3247 is a small molecule designed to inhibit AAK1, a protein kinase member of the notch pathway. It is being developed for the treatment of duchenne muscular dystrophy.
Product Name : SAT-3247
Product Type : Small molecule
Upfront Cash : Not Applicable
May 28, 2024
Lead Product(s) : SAT-3247
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable